Maria Grazia Roncarolo

List of Publications by Year
in descending order

63 papers	13,974 citations	81900 39 h-index	118850 62 g-index
65 all docs	65 docs citations	65 times ranked	14366 citing authors

#	Article	IF	Citations
1	The Women of FOCIS: Promoting Equality and Inclusiveness in a Professional Federation of Clinical Immunology Societies. Frontiers in Immunology, 2022, 13, 816535.	4.8	0
2	Downregulation of SATB1 by miRNAs reduces megakaryocyte/erythroid progenitor expansion in preclinical models of Diamondâ€“Blackfan anemia. Experimental Hematology, 2022, 111, 66-78.	0.4	2
3	Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing Î±Î² T cell-depleted haploidentical hematopoietic stem cell transplantation. Haematologica, 2021, 106, 847-858.	3.5	46
4	InsB9-23 Gene Transfer to Hepatocyte-Based Combined Therapy Abrogates Recurrence of Type 1 Diabetes After Islet Transplantation. Diabetes, 2021, 70, 171-181.	0.6	7
5	The Yin and Yang of Type 1 Regulatory T Cells: From Discovery to Clinical Application. Frontiers in Immunology, 2021, 12, 693105.	4.8	18
6	Development of Î²-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Science Translational Medicine, 2021, 13, .	12.4	82
7	BHLHE40 Regulates IL-10 and IFN-Î³ Production in T Cells but Does Not Interfere With Human Type 1 Regulatory T Cell Differentiation. Frontiers in Immunology, 2021, 12, 683680.	4.8	11
8	Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy. Cytotherapy, 2021, 23, 1017-1028.	0.7	5
9	Engineered type 1 regulatory T cells designed for clinical use kill primary pediatric acute myeloid leukemia cells. Haematologica, 2021, 106, 2588-2597.	3.5	11
10	Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. Science Translational Medicine, 2021, 13, eabf5264.	12.4	40
11	Co-Expression of FOXP3FL and FOXP3Î”2 Isoforms Is Required for Optimal Treg-Like Cell Phenotypes and Suppressive Function. Frontiers in Immunology, 2021, 12, 752394.	4.8	13
12	Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: Interim Results of a Global Phase 1 Study for Adult and Pediatric Patients. Blood, 2021, 138, 563-563.	1.4	4
13	Engineering Human Invariant Natural Killer T (iNKT) Cells to Overexpress Immunomodulatory Cytokines. Blood, 2021, 138, 3888-3888.	1.4	1
14	Coexpression of CD163 and CD141 identifies human circulating IL-10-producing dendritic cells (DC-10). Cellular and Molecular Immunology, 2020, 17, 95-107.	10.5	54
15	Celebrating 20 years of FOCIS. Science Immunology, 2020, 5, .	11.9	0
16	Regulatory Type 1 T Cell Infusion in Mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, S272-S273.	2.0	2
17	Gene therapy for Wiskott-Aldrich syndrome: History, new vectors, future directions. Journal of Allergy and Clinical Immunology, 2020, 146, 262-265.	2.9	31
18	Gene therapy for primary immunodeficiency. Human Molecular Genetics, 2019, 28, R15-R23.	2.9	55

#	Article	IF	Citations
19	Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2019, 10, 1342.	4.8	33
20	Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nature Communications, 2019, 10, 1634.	12.8	140
21	Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. Lancet Haematology,the, 2019, 6, e239-e253.	4.6	166
22	Lentiviral Gene Therapy in HSCs Restores Lineage-Specific Foxp3 Expression and Suppresses Autoimmunity in a Mouse Model of IPEX Syndrome. Cell Stem Cell, 2019, 24, 309-317.e7.	11.1	45
23	Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety. Molecular Therapy, 2018, 26, 917-931.	8.2	50
24	Role of human forkhead box P3 in early thymic maturation and peripheral T-cell homeostasis. Journal of Allergy and Clinical Immunology, 2018, 142, 1909-1921.e9.	2.9	17
25	Peanut-specific type 1 regulatory T cells induced inÂvitro from allergic subjects are functionally impaired. Journal of Allergy and Clinical Immunology, 2018, 141, 202-213.e8.	2.9	30
26	The Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases. Immunity, 2018, 49, 1004-1019.	14.3	230
27	Molecular and functional heterogeneity of IL-10-producing CD4+ T cells. Nature Communications, 2018, 9, 5457.	12.8	93
28	Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency. Journal of Allergy and Clinical Immunology, 2018, 142, 1679-1695.	2.9	106
29	Reprogramming human T cell function and specificity with non-viral genome targeting. Nature, 2018, 559, 405-409.	27.8	630
30	Engineered T Regulatory Type 1 Cells for Clinical Application. Frontiers in Immunology, 2018, 9, 233.	4.8	60
31	APVO210: A Bispecific Anti-CD86-IL-10 Fusion Protein (ADAPTIRâ„¢) to Induce Antigen-Specific T Regulatory Type 1 Cells. Frontiers in Immunology, 2018, 9, 881.	4.8	13
32	IL-10-Engineered Human CD4+ Tr1 Cells Eliminate Myeloid Leukemia in an HLA Class I-Dependent Mechanism. Molecular Therapy, 2017, 25, 2254-2269.	8.2	40
33	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers in Immunology, 2017, 8, 1844.	4.8	43
34	Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood, 2016, 128, 45-54.	1.4	173
35	InÂVivo Tracking of Human Hematopoiesis Reveals Patterns of Clonal Dynamics during Early and Steady-State Reconstitution Phases. Cell Stem Cell, 2016, 19, 107-119.	11.1	187
36	Insulin B chain 9â€“23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3 ⁺ T _{regs}. Science Translational Medicine, 2015, 7, 289ra81.	12.4	55

#	Article	IF	Citations
37	B-cell reconstitution after lentiviral vectorâ€“mediated gene therapy in patients with Wiskott-Aldrich syndrome. Journal of Allergy and Clinical Immunology, 2015, 136, 692-702.e2.	2.9	41
38	In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. Science Translational Medicine, 2015, 7, 273ra13.	12.4	160
39	Hurdles in therapy with regulatory T cells. Science Translational Medicine, 2015, 7, 304ps18.	12.4	136
40	Tr1 Cells and the Counter-Regulation of Immunity: Natural Mechanisms and Therapeutic Applications. Current Topics in Microbiology and Immunology, 2014, 380, 39-68.	1.1	191
41	B-cell development and functions and therapeutic options in adenosine deaminaseâ€“deficient patients. Journal of Allergy and Clinical Immunology, 2014, 133, 799-806.e10.	2.9	30
42	Regulatory T cells: recommendations to simplify the nomenclature. Nature Immunology, 2013, 14, 307-308.	14.5	537
43	Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy. Science, 2013, 341, 1233158.	12.6	998
44	Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome. Science, 2013, 341, 1233151.	12.6	900
45	Liver gene therapy by lentiviral vectors reverses antiâ€factor <scp>IX</scp> preâ€existing immunity in haemophilic mice. EMBO Molecular Medicine, 2013, 5, 1684-1697.	6.9	55
46	Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clinical Immunology, 2013, 146, 248-261.	3.2	186
47	Immune responses in liver-directed lentiviral gene therapy. Translational Research, 2013, 161, 230-240.	5.0	21
48	CD4 ⁺ T Cells from IPEX Patients Convert into Functional and Stable Regulatory T Cells by FOXP3 Gene Transfer. Science Translational Medicine, 2013, 5, 215ra174.	12.4	129
49	The Cellular and Molecular Mechanisms of Immuno-Suppression by Human Type 1 Regulatory T Cells. Frontiers in Immunology, 2012, 3, 30.	4.8	138
50	Rapamycin Combined with Anti-CD45RB mAb and IL-10 or with G-CSF Induces Tolerance in a Stringent Mouse Model of Islet Transplantation. PLoS ONE, 2011, 6, e28434.	2.5	36
51	Th17 Cells Express Interleukin-10 Receptor and Are Controlled by Foxp3â^' and Foxp3+ Regulatory CD4+ T Cells in an Interleukin-10-Dependent Manner. Immunity, 2011, 34, 554-565.	14.3	529
52	Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. European Journal of Immunology, 2011, 41, 1652-1662.	2.9	122
53	Hepatocyteâ€targeted expression by integraseâ€defective lentiviral vectors induces antigenâ€specific tolerance in mice with low genotoxic risk. Hepatology, 2011, 53, 1696-1707.	7.3	123
54	Molecular and functional characterization of allogantigen-specific anergic T cells suitable for cell therapy. Haematologica, 2010, 95, 2134-2143.	3.5	63

#	Article	IF	Citations
55	Induction of anergic allergen-specific suppressor T cells using tolerogenic dendritic cells derived from children with allergies to house dust mites. Journal of Allergy and Clinical Immunology, 2010, 125, 727-736.	2.9	51
56	Evidence for Long-term Efficacy and Safety of Gene Therapy for Wiskottâ€“Aldrich Syndrome in Preclinical Models. Molecular Therapy, 2009, 17, 1073-1082.	8.2	77
57	Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation. New England Journal of Medicine, 2009, 361, 478-488.	27.0	459
58	Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. Haematologica, 2009, 94, 1415-1426.	3.5	57
59	Interleukinâ€10â€secreting type 1 regulatory T cells in rodents and humans. Immunological Reviews, 2006, 212, 28-50.	6.0	1,071
60	Defective regulatory and effector T cell functions in patients with FOXP3 mutations. Journal of Clinical Investigation, 2006, 116, 1713-1722.	8.2	462
61	Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood, 2005, 105, 1162-1169.	1.4	435
62	Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning. Science, 2002, 296, 2410-2413.	12.6	1,081
63	A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature, 1997, 389, 737-742.	27.8	3,342